0 CHECKOUT

PRODUCT FILTERS

REGION

35
30
26
24
20

COUNTRY

12
10
8
3
3

PRICE

41
60
107
156

PUBLISHED

3
8
45
156

PRODUCT TYPE

149
2
1
1
1
1
1

Generic Drugs

The global generics market is fast growing, driven by demand for cost-effective medicines and new availability of high value products. By now there are 17 generic companies with revenues in excess of US$1 billion, while there were only 12 in 2008/09.

The reports, books, and subscriptions listed under Research and Markets’ Generic Drugs category cover every aspect of this industry, such as market trends, forecasts, drivers and restraints, etc. They will allow you to identify business opportunities and assess the strategies of the major players. You can also investigate the latest international and national patent opportunities across a vast number of INNs (international non-proprietary names), taking into account key concerns such as expiry dates, national regulations, etc.

Key players featured in our publications includes Teva Pharmaceutical, Mylan, Sandoz, Watson Pharmaceuticals, Greenstone, Par Pharma, Hospira, Apotex, Mallinckrodt, Dr. Reddy's, and more. Show Less
Read more

Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies

GBI Research's report ""Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies"" finds that the global herpes market is an attractive...

Published:  April 2012
Price:  From

Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution

GBI Research, the leading business intelligence provider, has released its latest research “Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent...

Published:  May 2012
Price:  From

Orphan Disease Therapeutic Disorders to 2018 - Emerging utics in GenAgents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity

GBI Research, the leading business intelligence provider, has released its latest research, “Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong...

Published:  May 2012
Price:  From

Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure

GBI Research, the leading business intelligence provider, has released its latest research “Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven...

Published:  April 2012
Price:  From

Assessment of the Japan Generics Industry

While Japan is the second largest pharma market globally, it has a very low penetration rate of generic drugs The country’s government has set an ambitious goal to enhance the generics penetration to...

Published:  March 2012
Price:  From

Top Ten ANDA / PARA-IV / API Opportunities To Be Targeted By Generic or Active Pharmaceutical Ingredient Companies

Top Ten ANDA / PARA-IV / API Opportunities To Be Targeted By Generic or Active Pharmaceutical Ingredient Companies Product Selection is one of the most crucial aspects of growth strategy for a generic...

Published:  March 2012
Price:  From

Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules

GBI Research, the leading business intelligence provider, has released its latest research “Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of...

Published:  January 2012
Price:  From

Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs

GBI Research, the leading business intelligence provider, has released its latest research “Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from...

Published:  February 2012
Price:  From

ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance

GBI Research, the leading business intelligence provider, has released its latest research, “ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to...

Published:  January 2012
Price:  From

The Impact of Generics on Pharmaceutical Growth Opportunities - A Growing Threat that Offers Future Opportunities

While generic penetration has been on the rise in the major developed markets for some time, the current and continuing difficult economic environment is stimulating political and payer actions to accelerate...

Published:  October 2011
Price:  From

Generic Drugs Market in Japan

Reports can include market size information, market access strategies, market share, export and import information, market analysis, market trends, competition, domestic production, best sales prospects,...

Published:  November 2011
Price: 

Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape

Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape Summary GBI Research’s...

Published:  October 2011
Price:  From

Multi-therapy Drugs: Opportunities for Generics & Biosimilars

Highly-detailed analysis, outlook & forecasts of 24 leading drugs which are indicated for a range of critical conditions Targeting multiple conditions is likely to increase a drug's potential target...

Published:  October 2011
Price:  From

Global Generics

Global Generics market was valued at US$123 billion in 2010, and has been estimated to reach US$ 180 billion by 2014, at a CAGR of 10 6% during 2011-14 Generics market remains a major growth area in...

Published:  August 2011
Price:  From

Hospital Injectable Drugs: Future Prospects for Generics & Biosimilars

The generic injectables sector exceeds US$11 2 billion and numerous high-value injectable products will face patent expiry in major markets over the next decade This critical new report evaluates the...

Published:  July 2011
Price:  From

Generic Drugs in Consumer Health Global Overview 2011

Generic drugs are usually associated with prescription (Rx) drugs; however, they are infiltrating the consumer health landscape via “branded generics” and private label across the world. Significant...

Published:  July 2011
Price:  From

Active Pharmaceutical Ingredients (API) Market in Asia-Pacific to 2016 - The Merchant Market for Generics Continues to Grow as the Competition Increases

“Active Pharmaceutical Ingredients (API) Market in Asia-Pacific to 2016 - The Merchant Market for Generics Continues to Grow as the Competition Increases” provides detailed insight into the Asia-Pacific...

Published:  July 2011
Price:  From

Generics Threats and Opportunities: Mounting an Effective Defense Strategy

After years of relatively easy blockbuster profits, worldwide respect and investment, and loyal customer bases, the Pharmaceutical realm has undergone a seismic shift Today, the branded Pharmaceutical...

Published:  June 2011
Price: 

Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues

Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues Summary GBI Research has released its research “Generic Growth Strategies - Manufacturers...

Published:  May 2011
Price:  From

Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market

“Sleep Disorders Market to 2017- Generics Substitution Coupled with a Weak Pipeline Will Negatively Impact the Market”, which provides insights into sleep disorders therapeutics sales and price forecasts...

Published:  April 2011
Price:  From
Loading Indicator

Our Clients